Lexicon Pharmaceuticals Inc（LXRX）财务数据LXRXLexicon Pharmaceuticals Inc

Evaluating the bottom line, Lexicon Pharmaceuticals, Inc. maintains a gross margin of 94.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3835.26%, while the net margin is -4591.76%. These profitability ratios, combined with a Return on Equity (ROE) of -40.21%, provide a clear picture of how effectively LXRX converts its operational activities into shareholder value.

In the context of the broader market, LXRX competes directly with industry leaders such as PCRX and OBX. With a market capitalization of $1.02B, it holds a significant position in the sector. When comparing efficiency, LXRX's gross margin of 94.36% stands against PCRX's 69.60% and OBX's N/A. Such benchmarking helps identify whether Lexicon Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Lexicon has demonstrated fluctuating revenue with significant milestones, including a revenue of 26,554,000 USD in Q4 2024 and a gross margin consistently above 90%, peaking at 99.89% in Q2 2025. Despite recent losses, the gross margin indicates strong operational efficiency.